Relmada Therapeutics with ticker code (RLMD) have now 6 analysts covering the stock. The analyst consensus points to a rating of ‘Strong_Buy’. The target price ranges between 75 and 38 with a mean TP of 62.83. Given that the stocks previous close was at 32.87 this indicates there is a potential upside of 91.1%. The day 50 moving average is 34.12 and the 200 moving average now moves to 38.03. The market capitalisation for the company is $534m. Company Website: http://www.relmada.com
Relmada Therapeutics, a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, an oral agent, which is in Phase II clinical trial for the treatment of depression, neuropathic pain, and other potential CNS pathological conditions. The company is also developing LevoCap ER, an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab, an oral dosage form of the opioid analgesic buprenorphine; and MepiGel, an orphan drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics was founded in 2004 and is headquartered in New York, New York.